The vif gene of lentiviruses has been demonstrated to be essential for efficient viral replication in many cell types. Although the Vif protein of feline immunodeficiency virus (FIV) displays limited homology to HIV-1 Vif, the role of vif in FIV replication is not known. We have examined the requirements of vif for replication of a FIV strain isolated from a non-domestic felid, Otocolobus manul (FIV-Oma). In agreement with others, we find that replication of FIV vif mutant molecular clones in CrFK cells is highly attenuated. Initial attempts to rescue vif mutant viruses in trans were limited by lack of detectable wild-type Vif expression from DNA constructs. We demonstrate that FIV-Oma Vif expression can be increased by re-synthesis of the gene to remove splice donor and acceptor sites as well as improving codon usage to a mammalian codon optimized model. Cellular localization of resynthesized Vif (Vif-RS) is cytoplasmic. Clonal stable transfectants expressing HA-tagged Vif-RS do not restore replication levels of vif mutant virus. However, in such cell lines, G-to-A mutation rates in replicating wild-type viruses are reduced.
Introduction
The viral infectivity factor (vif) is an accessory gene identified in all lentiviruses with the exception of equine infectious anemia virus (EIAV) (Kawakami et al., 1987; Oberste and Gonda, 1992) . Although sequence similarities among Vif proteins are limited between lentiviruses (Oberste and Gonda, 1992) , deletion or mutation of vif in human immunodeficiency virus type 1 (HIV-1) (Fisher et al., 1987; Gabuzda et al., 1992 Gabuzda et al., , 1994 Gibbs et al., 1994a; Strebel et al., 1987) and type-2 (HIV-2) (Michaels et al., 1993; Shibata et al., 1990) , simian immunodeficiency virus (SIV) (Gibbs et al., 1994b; Shibata et al., 1990) , caprine arthritis encephalitis virus (CAEV) (Harmache et al., 1996) , maedi-visna virus (MVV) (Kristbjornsdottir et al., 2004) and feline immunodeficiency virus (FIV) (Lockridge et al., 1999; Tomonaga et al., 1992 ) cause significant defects in viral replication in many primary lymphoid and myeloid cell lines termed "non-permissive" cells. However, in a subset of cell lines termed "permissive," HIV-1 vif appears dispensable for viral replication (Courcoul et al., 1995; Fan and Peden, 1992; Fisher et al., 1987; Maki et al., 1992) . The conflicting requirement of vif in viral replication has been resolved from studies differentiating cellular factors involved in HIV-1 viral replication in permissive and nonpermissive cell types (Madani and Kabat, 1998; Simon et al., 1998; Sheey et al., 2002) . A cellular protein, APOBEC3G, expressed exclusively in non-permissive cells, has been identified as the negative regulator of HIV-1 and SIV-1 vifdefective viral replication (Madani and Kabat, 1998; Sheey et al., 2002; Simon et al., 1998; Stopak et al., 2003; Yu et al., 2004a Yu et al., , 2004b . APOBEC3G, a member of the apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like (APOBEC) family of cytidine deaminases, is specifically packaged into HIV-1 virions and then blocks productive infection by catalyzing the deamination of deoxycytidine to deoxyuridine on the DNA minus strand during reverse transcription Jarmuz et al., 2002; Lecossier et al., 2003; Mangeat et Virology 361 (2007) 112 -122 www.elsevier.com/locate/yviro Zhang et al., 2003) . HIV-1 Vif abrogates the attenuation of HIV-1 vif mutant replication in non-permissive cells by recruiting an E3-ubiquitin ligase to APOBEC3G, thereby leading to its polyubiquitination, proteasomal degradation, and exclusion from assembling virus particles (Conticello et al., 2003; Marin et al., 2003; Sheehy et al., 2003; Yu et al., 2003) . In addition, HIV-1 Vif inhibits the translation of APOBEC3G mRNA, further reducing levels of the enzyme within the cell (Stopak et al., 2003) . Other members of the human APOBEC family, APOBEC3B and APOBEC3F, have also been associated with the inhibition of HIV-1 and HIV-2 replication (Bishop et al., 2004; Liddament et al., 2004; Wiegand et al., 2004; Zheng et al., 2004) . The vif gene of feline immunodeficiency virus (FIV) is similar in size and genome location to the vif gene of primate lentiviruses (Tomonaga et al., 1992) . It encodes a protein that is highly hydrophilic and basic from spliced viral transcripts containing rev-responsive elements. Similar to primate lentiviruses, the C-terminus of FIV Vif contains a consensus (SLQY (L/R)A) BC box motif. In HIV-1 Vif, this motif and an additional upstream zinc-finger motif has been demonstrated to complex with Cullin5, Elongin B, Elongin C, and Rbx1 to form a ubiquitin ligase (E3) complex which targets APOBEC3G and APOBEC3F for degradation (Mehle et al., 2006; Shirakawa et al., 2006; Yu et al., 2004a Yu et al., , 2004b . The conservation of the BC box motif in FIV Vif suggests that APOBEC3G inhibition may be a conserved function of lentivirus Vif proteins. In support of this, mutation of FIV Vif, including point mutations in the BC box, results in impaired cell-free infection of feline peripheral blood mononuclear cells (PBMCs) and established feline cell lines such as G355-5, CrFK, and MYA-1 (Lockridge et al., 1999; Shacklett and Luciw, 1994; Tomonaga et al., 1992) . Additionally, FIV vif has been shown to be necessary for efficient viral replication during in vivo infections of cats (Inoshima et al., 1996) . Although a cell line permissive for replication of vif-defective FIV strains has yet to be identified, Tomonaga et al. (1992) have shown that virus produced from CrFK cells transfected with a vif mutant molecular clone of FIV could infect a CD4+T-cell line (Mya 1) by co-cultivation of T-cells with virus producing CrFK cells. Thus, in this system, Vif expression appears necessary to achieve cell-free infectivity, but dispensable for virus spread via cell-to-cell contact.
To further elucidate the role of vif in the FIV lifecycle, we have attempted to rescue infection of FIV vif mutant virus by expression of Vif in trans. A molecular clone of FIV-Oma, derived from a highly cytopathic FIV strain from a Pallas cat (Barr et al., 1995 was utilized in this study due to this isolates replication efficiency and syncytium formation in CrFK cells compared to domestic FIV isolates (Barr et al., 1995) . In this study, we have found that mutant FIV-Oma infectious clones with frameshift and deletion mutations in vif, replicate at lower levels compared to wild-type virus in CrFK cells. Replication of vif mutant FIV could not be restored by expression of wild-type Vif in trans. However, levels of G-to-A mutations in proviral DNA are reduced by infection of wild-type virus in a Vif-expressing cell line. Thus, FIV Vif may function similarly to HIV-1 Vif in preventing APOBEC-induced mutagenesis of proviral DNA during reverse transcription.
Results

vif mutant virus replication is attenuated
Using the infectious clone of the FIV Oma strain, pOma3, as starting material, we generated two different vif mutant viruses (Fig. 1A) . The first, termed FIV VifΔ, was constructed by deleting the sequence between two unique StuI sites within the vif open reading frame. This deletion mutant removes 302 bp within the vif open reading frame (positions 325-626), however maintains predicted splice donor and acceptor sites within the resultant vif transcript. Additionally, a frameshift as a result of the deletion of the wild-type Vif protein adds eight missense codons after amino acid 109 and prematurely terminates translation. A second vif mutant, FIV Vif-fs, was created by insertion of a TA dinucleotide between base pairs 66 and 67 that forms a translation stop codon after amino acid 22. Since this mutant retains the complete vif sequence, it is unlikely that processing of the downstream subgenomic transcripts is altered in this mutant.
To assess the replication efficiency of vif mutant viruses, we transfected CrFK cells with molecular clones for wild-type virus (pOma3) and the two vif mutant viruses (FIV VifΔ and FIV Vif-fs). Monitoring of cell culture supernatant for reverse transcriptase (RT) activity, an indication of viral particle release, shows a peak in RT activity at day 11 for cells transfected with the wild-type virus that subsided at day 14, at which point cells displayed cytopathic effects (CPE) associated with viral replication (Fig. 1B) . Supernatant from cells transfected with FIV Vif-fs displayed detectable RT activity at levels approximately eightfold lower than the wild-type virus at day 11. These data suggest that low levels of viral particles are released from cells transfected with the FIV Vif-fs mutant clone; however, formation of viral particles or their release is impaired due to the vif mutation. RT activity above background could not be detected in supernatant of cells transfected with the FIV VifΔ virus (Fig. 1B) , indicating that viral replication is completely restricted in this clone. CPE were not observed in CrFK cells transfected with either vif-mutant molecular clone (data not shown).
Expression of tagged Oma3 Vif is not detectable in mammalian cells
To evaluate the role of vif in the FIV viral life cycle, we sought to generate lines of CrFK cells that express Vif. During the course of these experiments, achieving detectable levels of Vif protein expression proved problematic. In addition, FIVOma Vif was poorly antigenic in rabbits (data not shown) and, therefore, had to be fused to an epitope tag in order to visualize cellular localization and expression. In a first set of experiments, we cloned vif as a C-terminal fusion to enhanced green fluorescent protein (EGFP), referred to as EGFP-Vif, to monitor in vivo expression levels. In these experiments, transfection of control EGFP and EGFP-Vif expression vectors into CrFK cells produced detectable levels of fluorescence at 24 h posttransfection. However, when the expressed protein product was evaluated by western blot using an antibody against EGFP, the EGFP-Vif fusion protein exhibited a similar molecular weight as control EGFP ( Fig. 2A; compare lanes 2 and 3) . To test the ability of the EGFP-Vif construct to be properly translated, we expressed the EGFP-Vif fusion in bacteria. After a 2-h induction, western blots showed the EGFP-Vif fusion protein at approximately 70 kDa ( Fig. 2A, lane 4) . Thus, although the EGFP-Vif fusion protein was properly cloned and capable of being translated in bacteria, it appears to be poorly expressed in eukaryotic cells.
One possible explanation for the poor expression and truncation of Vif fusion constructs is the improper splicing of transcripts containing the vif open reading frame. The vif transcript sequence contains a predicted splice donor site between 24 and 25 nt (CAG/GUAAGU) and splice acceptor site between 689 and 690 nt (CUUACAG/AUCACCU) (Fig. 1A) . Splicing of sequence within the vif open reading frame is predicted to cause a frame shift resulting in the production of an 11 a.a. protein. To determine if use of these splice sites contributes to the truncation of Vif fusion proteins in eukaryotic cells, we performed RNase protection analysis of CrFK cells transfected with vectors expressing EGFP-Vif or HA-Vif. In this assay, truncated vif transcripts consistent with use of the predicted splice sites were protected by the vif probe ( Supplementary Fig. 1 ). We next created a truncated form of vif (Vif sd-) by removing the first 24 bp from the 5′ end of wild-type vif. The resulting open reading frame destroys the predicted splice donor site and produces an eight amino acid Nterminal truncation of the Vif protein. The truncated form of vif was fused in-frame to the C-terminus of EGFP, creating EGFPVif sd-. In CrFK cells transfected with the EGFP-Vif sd-vector, a poorly expressed protein product near to the predicted size of 58 kDa was detected by western blot (Fig. 2B , lane 2). The previous vector, EGFP-Vif, produced a shorter protein closer to the 28 kDa predicted size of control EGFP (Fig. 2B , lane 3). These observations suggest that the difficulty in translating fulllength Vif fusion proteins is due in part to splicing of the vif portion of transcripts.
Resynthesis of codon-optimized vif
Examination of the vif sequence from positions 5429 to 6187 bp of pOma3 shows that codon usage is most similar to that of prokaryotes, containing a high percentage of third codon position adenines (As) as opposed to guanines (Gs). Synonymous codon changes that better reflect mammalian codon usage and at the same time eliminated the splice donor and acceptor consensus sequences were made to improve Vif expression. The 252 codon vif was resynthesized with 42 synonymous codon changes using 21 overlapping oligonucleotides (Table 1 ). The reassembled vif gene was named vif-RS, and the sequence of this synthetic gene is shown in Fig. 3 .
Cellular localization of Vif
vif-RS was cloned as a C-terminal fusion to EGFP and the resultant expression construct was transfected into CrFK cells. A protein consistent with the predicted molecular weight of the EGFP-Vif-RS fusion protein was detected by western blot (Fig. 2B, lane 2) . To control for possible artifacts in Vif localization due to fusion to EGFP, a second Vif-RS fusion was made that replaces the EGFP reporter with an N-terminal 3X-HA epitope. Western blots of both stably and transiently transfected cells showed a reactive species near the predicted 35 kDa molecular weight of the HA-Vif-RS fusion (data not shown). The cellular localization of the HA-Vif-RS fusion was tested in CrFK cells stably transfected with the HA-Vif-RS expression vector. Immunofluorescence using an antibody for the HA epitope tag detected expression of HA-Vif-RS dispersed evenly throughout the cytoplasm; however, expression was excluded from the nucleus (Figs. 4C, D) . CrFK cells stably transfected with HA-Vif-RS and infected with Vif-Oma virus demonstrate cytoplasmic localization of both HA-Vif-RS (right panel) and FIV p24 Gag (left panel) (Figs. 4E, F) . Similar cytoplasmic staining for HA-Vif-RS has been observed in transiently transfected MDCK cells as well as in CrFK cells using fixation with either paraformaldehyde or methanol (data not shown).
HA-Vif-RS expression in trans does not rescue vif mutant FIV replication
The ability of Vif expression in trans to rescue attenuation of vif mutant FIV strains was tested in CrFK cells stably transfected with HA-Vif-RS. Two separate HA-Vif-RS-expressing clones were transfected with molecular clones for wildtype FIV-Oma, or vif mutant FIV VifΔ or FIV Vif-fs to (Fig. 5) . Additionally, virus replicating in HA-Vif-RS-expressing cells displayed higher RT activity and delayed CPE compared to replication in control cells (Fig. 5) . At the termination of the experiments due to virus-induced cell death at day 18 p.i. in control CrFK cells and at day 25 in HA-Vif-RS CrFK clones, HA-Vif-RS-expressing cells displayed 2.3-3 times the RT activity of control cells.
Vif expression in trans reduces mutation of pOma3 provirus in infection
If the FIV Vif protein acts in a similar manner to HIV Vif in blocking the packaging of cellular APOBEC3G, we hypothesized that Vif expression in trans might reduce deamination derived mutations in proviral DNA. We initiated infection of control CrFK cells and the two HA-Vif-RSexpressing clonal cell lines by infection with cell-free supernatant from pOma3 transfected cells. Plus-strand virion DNA was isolated from pelleted viral particles and the frequency of viral mutations was detected by PCR amplification of a 592 bp region in pol containing 118 Gs from each culture at 7 and 10 days p.i. PCR-amplified fragments were cloned and multiple clones were DNA sequenced. The resultant sequences were analyzed for G-to-A base changes indicative of cytidine deamination of the DNA minus strand.
In control FIV infected CrFK cells, G-to-A conversions were detected, averaging 2.18 and 2.61 sites per 118 Gs in the amplicon at day 7 and day 10, respectively (Table 2) . This compares to an average mutation rate of 0.27 and 0.16 changes per site at day 7 and day 10 for all other positions in the 592 bp pol region. The frequency of G-to-A exchanges in individual clones ranged from 0 to 7 at day 7 and 0 to 6 at day 10. In contrast, G-to-A exchanges were reduced in viral DNA to an average of 0.13 and 0 sites per 118 guanine positions in two separate HA-Vif-RS-expressing cell lines at day 7 (Table  2) . At day 10, a slight increase in G-to-A conversions was detected, averaging 0.5 to 0.38 sites per 118 Gs in FIV-Oma infected Vif-expressing cell lines. Individual clones contained between 0 and 2 G-to-A exchanges per sequence at day 10. Mutation rates of non-guanine positions in FIV pol ranged from 0.28 to 0.38 changes at day 7 and 0.21 to 0.23 changes at day 10 per 474 positions analyzed.
Discussion
In this study, we sought to better define the role of vif in the FIV viral life-cycle in light of recent studies in primate lentiviruses demonstrating a role for Vif in preventing APOBEC3G-induced cytosine deamination during minus strand synthesis. Similar to previous reports with different FIV isolates (Lockridge et al., 1999; Shacklett and Luciw, 1994; Tomonaga et al., 1992) , replication of several vif mutant viruses of a non-domestic cat isolate of FIV (FIV-Oma) displayed highly attenuated replication in CrFK cells compared to wildtype virus. As opposed to the primate lentiviruses (Blanc et al., 1993; Simon et al., 1995) , replication of vif mutant forms of FIV-Oma could not be restored by infection of cell lines stably expressing Vif in trans. However, wild-type viruses replicating in Vif-expressing cell lines displayed fewer G-to-A mutations, suggesting that FIV Vif may act in a manner similar to primate lentiviruses in preventing APOBEC3G-induced mutation of nascent viral DNAs.
We have observed differences in the replication kinetics of two separate FIV-Oma vif mutant viruses. The first mutant, containing a premature stop codon after amino acid 21 (FIV Vif-fs) maintained low levels of detectable RT activity in the supernatant of transfected cells that slightly increased over the course of 2 weeks. It is possible that the FIV Vif-fs virus is capable of maintaining low levels of virus production by direct cell-to-cell transmission previously reported for other FIV vif mutant viruses (Shacklett and Luciw, 1994; Tomonaga et al., 1992) . However, FIV Vif-fs does not appear capable of initiating cell-free infection as filtered supernatant from transfected CrFK cells was unable to initiate de novo infection in CrFK cells (data not shown). A second vif mutant, FIV VifΔ, a 117 amino acid truncated form of FIV Vif, had undetectable RT activity suggesting that both cell-to-cell and cell-free transmission are completely restricted. As the FIV VifΔ mutant possesses a deletion from positions 325 to 626 bp of vif, we cannot rule out that the phenotype of the FIV VifΔ mutant is attributed to the disruption of viral regulatory sequences within the mutation site affecting the expression of downstream genes orf2, env, and rev. However, vif transcripts in both mutant viruses retain predicted splice donor and acceptor sites (Fig. 1A) . Thus, additional regulatory sites within the deleted region might be disrupted as a result of the 302 bp deletion in the FIV VifΔ mutant.
Our attempts to rescue the phenotype of the FIV-Oma vif mutants were hindered by poor expression of Vif in cell culture. High levels of HIV-1 Vif expression have also been difficult to achieve due to inefficient nuclear export of vif transcripts, poor mammalian codon usage, and high turnover rate of Vif protein Nguyen et al., 2004; Wang et al., 2005) . Restricted vif-expression levels may represent a selective advantage for retroviral replication. Akari et al. (2004) suggested that high protein turnover rates of HIV-1 Vif prevent the improper processing of Gag polyproteins during virus maturation. Cells over-expressing HIV-1 Vif accumulate Gag processing intermediates and exhibit impaired replication rates compared to cells expressing Vif at physiological levels . Interestingly, we found that wild-type FIVOma replication in FIV Vif-expressing cells displays delayed replication kinetics and attains higher supernatant RT activity before the onset of virus-induced cytopathic effects. This suggests that high levels of FIV Vif expression in our system may have negative consequences on the replication of wild-type FIV.
In the course of our studies, we found that aberrant RNA splicing of vif transcripts contributed to the truncation of Vif fusion protein products. Aberrant vif splicing is conceivably a consequence of removing vif gene expression from the context of the viral genome and rev dependency. This became apparent when comparing the splicing pattern of vif transcripts during wild-type FIV infection and in cells where Vif was expressed independently of the FIV genome ( Supplementary  Fig. 1 ). When expressed alone, about one-half of the detected vif transcripts utilized splice donor and acceptor sites contained within the vif open reading frame. This splicing event is predicted to truncate the vif open reading frame and create a premature stop codon leading to the expression of an 11 amino acid peptide. During FIV infection of CrFK cells, the majority of the subgenomic vif transcripts comprise the full-length open reading frame. Although internally spliced vif transcripts were detected during FIV infection, the low intensity of these bands suggests that these represent a minor fraction of the vifcontaining RNAs.
Our data that FIV-Oma Vif expression is confined to the cytoplasm correlate with reports in HIV-1 (Goncalves et al., 1994 (Goncalves et al., , 1995 Simon et al., 1997) and MVV (Audoly et al., 1992) infected cells. Expression in the cytoplasm would be consistent with a role of the Vif protein in regulating FIV virus maturation or modifying the infectivity of the virus after entry into a host cell by preventing APOBEC3G incorporation into virions. The cytoplasmic localization of HA-tagged Vif in cells infected with FIV-Oma contradicts a previous report showing FIV Vif expression in the nucleus. In this report, Chatterji et al. (2000) demonstrated that the subcellular localization of Vif in a feline astrocyte cell line, G355, infected with the FIV 34TF10 strain, differed depending upon the cellular fixation method prior to immunostaining; Vif localization appeared cytoplasmic in cells fixed with methanol and nuclear in cells fixed with 2% formaldehyde. Our results indicate that FIV-Oma Vif expression is invariably cytoplasmic in CrFK cells using either methanol or paraformaldehyde fixation. Thus, FIV Vif subcellular localization may vary between domestic and non-domestic cat strains of FIV or may differ depending upon the cell type in which it is expressed.
A surprising finding in our study is that Vif expression in trans was unable to rescue the replication of vif mutant viruses. This result differs from published studies demonstrating that HIV-1 Vif expression can abrogate the replication block for vif- mutated viruses in non-permissive cells by preventing APO-BEC3G incorporation into virions . As members of the APOBEC3 family appear conserved throughout vertebrate evolution, Vif proteins of lentiviruses from primates and sheep (Kristbjornsdottir et al., 2004) have co-evolved to counteract the host anti-viral mechanism. Recent studies by Poss et al. (2006) and Lochelt et al. (2005) indicate that the APOBEC3-mediated mechanism of retroviral inhibition is conserved in felines. In support of this, the feline foamy virus Bet protein has been demonstrated to bind a feline APOBEC3 orthologue (fe3) and inhibit the cytidine deamination of the spumavirus genome (Lochelt et al., 2005) . Our finding that fewer G-to-A mutations in wild-type FIV-Oma replicating in CrFK cells stably overexpressing FIV-Oma Vif suggests that FIV Vif is capable of preventing APOBEC-induced mutations in cells from domestic cats. However, the inability of Vif expression in trans to restore infectivity of vif mutant viruses suggests that additional functions of FIV Vif are not complimented in our system. It is possible that the spatial or temporal expression of Vif in our studies may not adequately reflect the native behavior of a multifunctional protein. Analysis of the interaction of FIV Vif and the feline APOBEC3 orthologue (fe3) will facilitate a further understanding of the function of FIV Vif in viral replication.
Materials and methods
Cell lines and virus
The FIV-Oma strain isolated from Pallas' cat used in this study has been previously described (Barr et al., 1995 . pOma3 is an infectious molecular clone derived from the FIV-Oma isolate. The sequence of the pOma3 proviral clone has been deposited in GenBank, accession number AY713445.
CrFK cells (ATCC CCL-94) were grown in 70% MEM-H, 30% L-15 and 10% FBS supplemented with 25 mM HEPES and 50 μg/mL gentamicin. MDCK cells (ATCC CCL-34) were grown in MEM medium containing10% FBS and 50 μg/mL gentamicin. Both cell lines were grown in 37°C incubators with 5% CO 2 . All transfections were done using Lipofectamine according to the manufacturer's protocols (Invitrogen). Clonal cell lines derived from CrFK cells transfected with the HA-Vif-RS vector were selected with 100 μg/mL zeocin in the same medium. The DNA sequence of the vif open reading frame was verified in both clonal cell lines expressing HA-Vif-RS.
Vif cloning, subcloning and expression
The FIV-Oma vif open reading frame was amplified from pOma3 employing a forward primer 5′-AGATCTAT-GAGTGGTGAAGAG-3′and a reverse primer 5′-GTCGACT-TAACTCTTCATCCGA-3′ with Pfu polymerase (Stratagene) (94°C for 30 s, 50°C for 30 s, 72°C for 45 s) for 25 cycles. The product was confirmed by DNA sequencing and cloned into the pCR2.1 Topo TA cloning vector generating pvif/TA1. The resultant plasmid was then cut with EcoRV/SalI to isolate the vif fragment, which was subsequently cloned into pCDNA4/ HisMaxC digested with EcoRV/XhoI for mammalian expression studies.
Fusion proteins of Vif and EGFP were created by digesting pvif/TA1 with PstI and BamHI and cloning the vif fragment into the pEGFP-C3 vector (Clontech) digested with PstI and BamHI to create an N-terminal EGFP-Vif fusion. A BglII/SalI fragment from pvif/TA1, which deletes the 5′ portion of vif through the predicted splice donor site, was cloned into EGFP-C1 generating the vector EGFP-Vif sd-. Transient transfections with these plasmids were done for 48 h, and then cells were collected and frozen at minus 70°C.
To express Vif in bacteria, an EcoRV/SalI fragment from pvif/TA1 was cloned into the bacterial expression vector pET28c (Novagen) cut with Ecl136II/XhoI. Additionally, the EGFP-Vif fusion was cloned as an NcoI/SalI fragment from pEGFP-Vif into the multiple cloning site of pET28a (Novagen) digested with NcoI and SalI. These pET28-vif plasmids were transformed into BL21DE3pLysS cells that were subsequently treated with IPTG for 2 h to induce Vif protein expression.
Generation of vif mutant FIV strains
FIV pOma3 VifΔ molecular clone was constructed by digesting pOma3 with StuI and self-ligating the two unique enzyme sites within the vif open reading frame. FIV Vif-fs was made by site-directed mutagenesis of pOma3 using primers forward 5′ -G GG GG A C C TA GATA A GA GC TATG C -TATGCTCTATATAGG-3′ and reverse 5′-CCTATATAGAG-CAT AGCATAGCTCTTATCTAGGTCCCCC-3′with the QuikChange kit from Stratagene. The primers insert a TA dinucleotide (sequence underlined) at 67 bp within the vif open reading frame causing the mutation of a SapI enzyme site and forming premature termination codons. Following the construction of both mutant molecular clones, DNA sequencing verified that no additional sequence changes were introduced during the cloning process. Infectivity of the molecular clones was measured by a reverse transcriptase assay, using procedures previously described . Aliquots from three independent transfections were measured for RT activity at each time point.
vif resynthesis FIV-Oma vif gene was resynthesized using the primers shown in Table 1 . Amplification in 100 μL was as follows: primer vif 1 and vif 2 at 1 nM, Taq polymerase ten cycles of 94°C for 30 s, 40°C for 30 s and 72°C for 30 s then five cycles of 94°C for 30 s and 72°C for 30 s. PCR products were electrophoresed in 2% Nusieve gels, and bands were gelpurified and added to the second amplification using adjacent primer sets (e.g. vif 1 and vif 3). After synthesis with primers vif 1-6, vif 5F-12 and vif 11F-19, products were cloned in to pCR2.1Topo TA vector and multiple clones were sequenced. Reassembly of resynthesized vif gene was accomplished by cloning vif 1-6 cut with BamHI and EcoRI into pBluescript SK (−), followed by digestion of the resultant clone and vif 5F-12 with StyI and EcoRI and ligation. The vif 11F-19 clone and the Bluescript clone of vif 1-12 were then digested with EcoNI and XhoI and fragments were ligated. The resultant vif clone was named vif-RS. All DNA sequencing was performed at the core facility at Cornell University Bioresource Center (Ithaca, NY).
For mammalian expression, the vif-RS digested with BamHI and XhoI was subcloned into pEGFP-C1 cut with BglII and SalI, to create an N-terminal EGFP fusion, EGFP-Vif-RS. The same fragment was cloned into pCDNA4hismaxC cut with BamHI and XhoI. This plasmid was then digested with SnaBI and BamHI and ligated with a fragment containing a 3XHA tag derived from the plasmid (a generous gift from Dr. Jun-Lin Guan, Cornell University) digested with similar enzymes. This process exchanges the CMV promoter and Xpress epitope of pCDNA4hismaxC with the CMV promoter and 3X HA tag of pKH3-FAK to create the HA-Vif-RS expression construct.
Western blots and immunofluorescence
Cell lysates used for western blots were dissolved in Nupage (Invitrogen) sample buffer, boiled and run on Nupage 4-12% Bis-Tris gels in MOPS buffer and electroblotted to nitrocellulose as described in the manufacturer's protocol. Membranes were probed with antibodies to anti-HA (Upstate), anti-GFP (Invitrogen) and anti-FIV p24 (Biodesign International) followed by incubation with species-specific secondary antibodies conjugated to alkaline phosphatase. Immunoreactive bands were detected with BCIP/NBT staining (KPL).
For indirect immunofluorescence staining, CrFK or MDCK cells expressing HA-Vif-RS were grown to approximately 50% confluency on 12-mm-diameter coverslips pretreated with 10 mg of poly-L-lysine per milliliter to aid cell attachment and spreading. For FIV Gag localization, CrFK cells were infected with supernatant from pOma3 transfected cells. Cells were fixed with either ice-cold 100% methanol for 10 min or 3% paraformaldehyde in PBS (pH 7.4) for 15 min. Paraformaldehyde fixed cells were quenched with 50 mM NH 4 Cl and permeabilized with 0.1% Triton X-100. After being blocked in 10% goat serum, cells were treated with mouse anti-FIV p24 IgG or rabbit anti-HA for 30 min. As secondary antibodies, we used Texas red (TR)-labeled goat anti-mouse immunoglobulin G and fluorescein isothiocyanate (FITC)-labeled goat antirabbit immunoglobulin G (Zymed). Coverslips were mounted with Vecta-shield (Vector Laboratories) containing DAPI stain. Cells were viewed and photographed on a Zeiss Axiophot or confocal microscope.
RNase protection
pvif/TA9 (opposite orientation of the PCR-cloned vif insert to pvif/TA1) was linearized with DraI in order to make an antisense transcript containing 138 nt from the 3′ end of vif and 78 nt of vector sequence (216 nt total). In vitro transcription was performed with T7 RNA polymerase, using Ambion's RPA III kit. Total RNA from transfected and infected CrFK cells was prepared with the Rneasy kit (Qiagen). 8 × 10 4 cpm of in vitro transcripts was annealed overnight to10 μg of total RNA. A 10-bp ladder (Invitrogen) was labeled by a kinase-exhange reaction with γ-ATP. Samples were electrophoresed on Novex 7% acrylamide TBE/urea gels and exposed to X-ray film.
Analysis of mutations in replicating FIV
CrFK cells were transfected with the FIV-Oma infectious clone pOma3 using Lipofectamine reagent (Invitrogen). Five days post-transfection, equal volumes of supernatant were used to infect 1 × 10 6 control CrFK cells as well as two clonal CrFK cell lines expressing HA-Vif-RS. Infection of each line was verified using indirect immunofluorescence staining procedures described above. At 7 and 10 days post-infection, viral pellets were prepared as previously described (Kristbjornsdottir et al., 2004) . Virion incorporated DNA was isolated with a DNA Blood Mini Kit (Qiagen). Aliquots of 100 ng of DNA were utilized in PCR reactions with a high fidelity Taq polymerase (Invitrogen) using forward primers 5′-TAAGCAATGGCCTC-TATCAAAA-3′ and reverse primers 5′-TAAAGCAATGG CCTCTATCAAAA-3′ and conditions as follows: 94°C for 30 s, 50°C for 1 min and a 68°C extension for 1 min, for 35 cycles. The resultant PCR products encompassing positions 2585-3177 within the pol region of pOma3 were cloned into the pCR2.1 TA cloning vector. Fifteen independent cloned products were DNA sequenced using M13F and M13R primers and analyzed for DNA mutations.
